Institute of Metabolic and Cardiovascular Diseases (I2MC), INSERM, Toulouse University, 31000 Toulouse, France.
Department of Urology, CHU-Institut Universitaire du Cancer de Toulouse, 31000 Toulouse, France.
Int J Mol Sci. 2022 Oct 4;23(19):11747. doi: 10.3390/ijms231911747.
Bladder cancer is the 10th most common cancer in the world and has a high risk of recurrence and metastasis. In order to sustain high energetic needs, cancer cells undergo complex metabolic adaptations, such as a switch toward aerobic glycolysis, that can be exploited therapeutically. Reactive oxygen species (ROS) act as key regulators of cancer metabolic reprogramming and tumorigenesis, but the sources of ROS remain unidentified. Monoamine oxidases (MAOs) are mitochondrial enzymes that generate HO during the breakdown of catecholamines and serotonin. These enzymes are particularly important in neurological disorders, but recently, a new link between MAOs and cancer has been uncovered, involving their production of ROS. At present, the putative role of MAOs in bladder cancer has never been evaluated. We observed that human urothelial tumor explants and the bladder cancer cell line AY27 expressed both MAO-A and MAO-B isoforms. Selective inhibition of MAO-A or MAO-B limited mitochondrial ROS accumulation, cell cycle progression and proliferation of bladder cancer cells, while only MAO-A inhibition prevented cell motility. To test whether ROS contributed to MAO-induced tumorigenesis, we used a mutated form of MAO-A which was unable to produce HO. Adenoviral transduction of the WT MAO-A stimulated the proliferation and migration of AY27 cells while the Lys305Met MAO-A mutant was inactive. This was consistent with the fact that the antioxidant Trolox strongly impaired proliferation and cell cycle progression. Most interestingly, AY27 cells were highly dependent on glucose metabolism to sustain their growth, and MAO inhibitors potently reduced glycolysis and oxidative phosphorylation, due to pyruvate depletion. Accordingly, MAO inhibitors decreased the expression of proteins involved in glucose transport (GLUT1) and transformation (HK2). In conclusion, urothelial cancer cells are characterized by a metabolic shift toward glucose-dependent metabolism, which is important for cell growth and is under the regulation of MAO-dependent oxidative stress.
膀胱癌是全球第 10 大常见癌症,具有较高的复发和转移风险。为了维持高能量需求,癌细胞经历复杂的代谢适应,例如转向有氧糖酵解,这可以在治疗上得到利用。活性氧 (ROS) 作为癌症代谢重编程和肿瘤发生的关键调节剂,但其来源仍未确定。单胺氧化酶 (MAO) 是线粒体酶,在儿茶酚胺和 5-羟色胺分解过程中产生 HO。这些酶在神经疾病中尤为重要,但最近发现 MAO 与癌症之间存在新的联系,涉及它们产生 ROS。目前,MAO 在膀胱癌中的潜在作用从未得到评估。我们观察到人尿路上皮肿瘤外植体和膀胱癌细胞系 AY27 均表达 MAO-A 和 MAO-B 同工型。选择性抑制 MAO-A 或 MAO-B 可限制线粒体 ROS 积累、细胞周期进程和膀胱癌细胞增殖,而仅抑制 MAO-A 可防止细胞迁移。为了测试 ROS 是否有助于 MAO 诱导的肿瘤发生,我们使用了一种无法产生 HO 的 MAO-A 突变形式。WT MAO-A 的腺病毒转导刺激了 AY27 细胞的增殖和迁移,而 Lys305Met MAO-A 突变体则无活性。这与抗氧化剂 Trolox 强烈抑制增殖和细胞周期进程的事实一致。最有趣的是,AY27 细胞高度依赖葡萄糖代谢来维持其生长,MAO 抑制剂由于丙酮酸耗尽而强烈抑制糖酵解和氧化磷酸化。因此,MAO 抑制剂降低了参与葡萄糖转运 (GLUT1) 和转化 (HK2) 的蛋白质的表达。总之,尿路上皮癌细胞的特征是向葡萄糖依赖性代谢的代谢转变,这对细胞生长很重要,并且受 MAO 依赖性氧化应激的调节。